Volume 16, Issue 12, December 2015, Pages 1462–1481
Open Access
Highlights
- •
- This systematic review provides up-to-date and comprehensive evidence of the efficacy and safety of Chinese herbal medicine for insomnia.
- •
- Findings from this review reveal that Chinese herbal medicine improves subjective sleep quality and quantity in people with insomnia.
- •
- Findings also show that there is no significant difference between Chinese herbal medicine and placebo with respect to the frequency and severity of adverse events.
- •
- Conclusions cannot be drawn on the comparative effectiveness between Chinese herbal medicine and benzodiazepine drugs or psychotherapy due to heterogeneity.
Abstract
This
systematic review is to evaluate the efficacy and safety of Chinese
herbal medicine (CHM) for people with insomnia. Randomized controlled
trials (RCTs) investigating oral CHM alone or in combination with
conventional therapies for primary insomnia were identified by searching
English and Chinese publications and databases of clinical trial
registration. Risk of bias was assessed according to the Cochrane
Handbook 5.1. Meta-analysis was conducted using RevMan 5.2.4.
Seventy-nine trials (7886 participants) were finally included in the
review, and 76 were included in the meta-analysis. Twenty-seven trials
reported the methods of random sequence generation, and five of them
used the allocation concealment. Blinding of participants and personnel
were used in 10 studies. The main meta-analysis showed that CHM alone
was more effective than placebo by reducing scores of Pittsburgh Sleep
Quality Index (mean difference, MD: −3.06, 95% confidence interval, CI:
−5.14 to −0.98, I2 = 97%) and benzodiazepine drugs (BZDs) (MD: −1.94, 95% CI: −2.45 to −1.43, I2
= 96%). The effect was also seen when CHM was combined with BZDs
compared with placebo plus BZDs (MD: −1.88, 95% CI: −2.78 to −0.97, I2 = 0%) or cognitive and behavioral therapy (MD: −3.80, 95% CI: −4.91 to −2.68, I2
= 68%) alone. There was no significant difference between CHM and
placebo regarding the frequency of adverse events (relative risk, RR:
1.65, 95% CI: 0.67–4.10, I2 = 0). Overall, oral CHM
used as a monotherapy or as an adjunct to conventional therapies appears
safe, and it may improve subjective sleep in people with insomnia.
However, the typical effect of CHM for insomnia cannot be determined due
to heterogeneity. Further study focusing on individual CHM formula for
insomnia is needed. The development of a comparable placebo is also
needed to improve the successful blinding in RCTs.
